Patents by Inventor Dhaya Seshasayee

Dhaya Seshasayee has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Agonists of TREM2
    Patent number: 12384844
    Abstract: This application discloses, inter alia, certain antibodies that specifically bind to human TREM2 (triggering receptor expressed on myeloid cells 2). In some embodiments, the antibodies act as TREM2 agonists. In some embodiments, antibodies herein specifically bind to the stalk region of intact, human TREM2, without binding to soluble TREM2, which is the product of TREM2 cleavage between residues H157 and S158. In some embodiments, the antibodies act as TREM2 agonists, specifically bind to the stalk region of TREM2 with dissociation constants ranging from 10 nM to as low as 100-500 pM, 10-50 pM, or 1-10 pM, specifically bind to a TREM2 epitope spanning the H157-S158 cleavage site, and do not bind to soluble TREM2.
    Type: Grant
    Filed: May 12, 2022
    Date of Patent: August 12, 2025
    Assignee: Genentech, Inc.
    Inventors: Ainhoa Echeverria Larraza, David Verne Hansen, Isidro Hotzel, Yi-Chun Hsiao, Zhonghua Lin, Dhaya Seshasayee, Benny Chih
  • ANTI-Ly6E ANTIBODIES, IMMUNOCONJUGATES, AND USES THEREOF
    Publication number: 20250122280
    Abstract: The invention provides anti-Ly6E antibodies and immunoconjugates, and methods of using the same.
    Type: Application
    Filed: October 25, 2024
    Publication date: April 17, 2025
    Applicant: Genentech, Inc.
    Inventors: Nicholas John Agard, Thomas Harden Pillow, Josefa Dela Cruz Chuh, Mary Ann T. Go, Katherine R. Kozak, Zhonghua Lin, Dhaya Seshasayee, Shang-Fan Yu, James Thomas Koerber, Yonglian Sun
  • ISOFORM-SELECTIVE ANTI-TGF-BETA ANTIBODIES AND METHODS OF USE
    Publication number: 20240279322
    Abstract: The invention provides isoform-selective anti-TGF? antibodies and methods of using the same. In particular, isoform-selective anti-TGF?2, anti-TGF?3, and anti-TGF?2/3 monoclonal antibodies are provided, e.g., for the treatment of fibrosis and other TGF?-related disorders.
    Type: Application
    Filed: January 23, 2024
    Publication date: August 22, 2024
    Inventors: Wei-Ching Liang, Joseph R. Arron, Daryle DePianto, Wendy Green Halpern, WeiYu Lin, Patrick J. Lupardus, Thirumalai Rajan Ramalingam, Dhaya Seshasayee, Tianhe Sun, Tulika Tyagi, Jia Wu, Yan Wu, Jian Ping Yin
  • Isoform-selective anti-TGF? antibodies and methods of use
    Patent number: 11919948
    Abstract: The invention provides isoform-selective anti-TGF? antibodies and methods of using the same. In particular, isoform-selective anti-TGF?2, anti-TGF?3, and anti-TGF?2/3 monoclonal antibodies are provided, e.g., for the treatment of fibrosis and other TGF?-related disorders.
    Type: Grant
    Filed: March 18, 2021
    Date of Patent: March 5, 2024
    Assignee: GENENTECH, INC.
    Inventors: Wei-Ching Liang, Joseph R. Arron, Daryle Depianto, Wendy Green Halpern, WeiYu Lin, Patrick J. Lupardus, Thirumalai Rajan Ramalingam, Dhaya Seshasayee, Tianhe Sun, Tulika Tyagi, Jia Wu, Yan Wu, Jian Ping Yin
  • Anti-interleukin-33 antibodies and uses thereof
    Patent number: 11760797
    Abstract: The invention provides interleukin-33 (IL-33) antibodies and methods of making and using the same, e.g., for treatment of IL-33 mediated disorders (e.g., ocular disorders such as AMD (e.g., geographic atrophy (GA)).
    Type: Grant
    Filed: March 12, 2021
    Date of Patent: September 19, 2023
    Assignee: Genentech, Inc.
    Inventors: Gerald R. Nakamura, Dhaya Seshasayee, Menno Van Lookeren Campagne, Tiffany Wong, Jia Wu, Hongkang Xi, Jack Bevers, III, Hiu Nam Chan, Laetitia Comps-Agrar, Racquel Corpuz
  • Anti-interleukin-33 antibodies and uses thereof
    Patent number: 11725050
    Abstract: The invention provides interleukin-33 (IL-33) antibodies and methods of using the same.
    Type: Grant
    Filed: June 16, 2020
    Date of Patent: August 15, 2023
    Assignee: Genentech, Inc.
    Inventors: Philip E. Hass, Meredith Hazen, Yi-Chun Hsiao, Rajita Khosla, Gerald R. Nakamura, Dhaya Seshasayee, Menno Van Lookeren Campagne, Hongkang Xi, Wenwu Zhai, Jack Bevers, III, Nancy Chiang
  • Agonists of TREM2
    Publication number: 20220389097
    Abstract: This application discloses, inter alia, certain antibodies that specifically bind to human TREM2 (triggering receptor expressed on myeloid cells 2). In some embodiments, the antibodies act as TREM2 agonists. In some embodiments, antibodies herein specifically bind to the stalk region of intact, human TREM2, without binding to soluble TREM2, which is the product of TREM2 cleavage between residues H157 and S158. In some embodiments, the antibodies act as TREM2 agonists, specifically bind to the stalk region of TREM2 with dissociation constants ranging from 10 nM to as low as 100-500 pM, 10-50pM, or 1-10 pM, specifically bind to a TREM2 epitope spanning the H157-S158 cleavage site, and do not bind to soluble TREM2.
    Type: Application
    Filed: May 12, 2022
    Publication date: December 8, 2022
    Applicant: Genentech Inc.
    Inventors: Ainhoa Echeverria Larraza, David Verne Hansen, Isidro Hotzel, Yi-Chun Hsiao, Zhonghua Lin, Dhaya Seshasayee, Benny Chih
  • Anti-interleukin-33 antibodies and uses thereof
    Patent number: 10723795
    Abstract: The invention provides interleukin-33 (IL-33) antibodies and methods of using the same.
    Type: Grant
    Filed: August 31, 2018
    Date of Patent: July 28, 2020
    Assignee: Genentech, Inc.
    Inventors: Philip E. Hass, Meredith Hazen, Yi-Chun Hsiao, Rajita Khosla, Gerald R. Nakamura, Dhaya Seshasayee, Menno Van Lookeren Campagne, Hongkang Xi, Wenwu Zhai, Jack Bevers, III, Nancy Chiang
  • Anti-interleukin-33 antibodies and uses thereof
    Patent number: 10093730
    Abstract: The invention provides interleukin-33 (IL-33) antibodies and methods of using the same.
    Type: Grant
    Filed: November 10, 2015
    Date of Patent: October 9, 2018
    Assignee: Genentech, Inc.
    Inventors: Philip E. Hass, Meredith Hazen, Yi-Chun Hsiao, Rajita Khosla, Gerald R. Nakamura, Dhaya Seshasayee, Menno Van Lookeren Campagne, Hongkang Xi, Wenwu Zhai, Jack Bevers, III, Nancy Chiang
  • Anti-TIGIT antibodies and methods of use
    Patent number: 10047158
    Abstract: The invention provides anti-TIGIT (T-cell immunoreceptor with Ig and ITIM domains) antibodies and methods of using the same.
    Type: Grant
    Filed: February 13, 2018
    Date of Patent: August 14, 2018
    Assignee: Genentech, Inc.
    Inventors: Jane L. Grogan, Robert J. Johnston, Yan Wu, Wei-Ching Liang, Patrick Lupardus, Mahesh Yadav, Dhaya Seshasayee, Meredith Hazen
  • Anti-tigit antibodies and methods of use
    Patent number: 10017572
    Abstract: The invention provides anti-TIGIT (T-cell immunoreceptor with Ig and ITIM domains) antibodies and methods of using the same.
    Type: Grant
    Filed: September 23, 2016
    Date of Patent: July 10, 2018
    Assignee: Genentech, Inc.
    Inventors: Jane L. Grogan, Robert J. Johnston, Yan Wu, Wei-Ching Liang, Patrick Lupardus, Mahesh Yadav, Dhaya Seshasayee, Meredith Hazen
  • Polypeptides That Bind Br3 and Uses Thereof
    Publication number: 20080181888
    Abstract: The present invention relates to novel BR3 binding antibodies and polypeptides, including antagonist and agonist polypeptides. The present invention also relates to the use of the BR3 binding antibodies and polypeptides in, e.g., methods of treatment, screening methods, diagnostic methods, assays and protein purification methods.
    Type: Application
    Filed: December 23, 2005
    Publication date: July 31, 2008
    Inventors: Christine M. Ambrose, Mercedesz Balazs, Laura DeForge, Mark S. Dennis, Germaine Fuh, Stephen D. Hurst, Chingwei V. Lee, Henry B. Lowman, Flavius Martin, Gerald R. Nakamura, Dhaya Seshasayee, Melissa Starovasnik, Jeffrey S. Thompson